James Atkins to Furans
This is a "connection" page, showing publications James Atkins has written about Furans.
Connection Strength
0.089
-
Arnold SM, Moon J, Williamson SK, Atkins JN, Ou SH, LeBlanc M, Urba SG. Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Invest New Drugs. 2011 Apr; 29(2):352-9.
Score: 0.089